Sign in

CIK 0001422143

  • Non-accelerated filer
  • Smaller reporting company

Kura Oncology, Inc.

Sign in to watch
Ticker
KURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
611547851
Phone
+1 858-500-8800
Business address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
Former names
ZETA ACQUISITION CORP III
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Planned sale Chief Legal Officer sold 1,559 shares at $5.96 ($9,292)
  6. 4 Planned sale Chief Operating Officer sold 1,558 shares at $6.28 ($9,777)
  7. 4 Open-market sale Director sold 22,682 shares at $8.00 ($181,456)
  8. 4 Open-market sale SVP, Finance & Accounting sold 4,949 shares at $7.87 ($38,958)
  9. 4 Open-market sale Chief Medical Officer sold 4,963 shares at $7.87 ($39,068)
  10. 4 Open-market sale Chief Legal Officer sold 7,281 shares at $7.87 ($57,315)
  11. 4 Open-market sale Chief Operating Officer sold 1,817 shares at $7.87 ($14,303)
  12. 4 Open-market sale Chief Scientific Officer sold 2,166 shares at $7.87 ($17,051)
  13. 4 Open-market sale Chief Commercial Officer sold 1,583 shares at $7.87 ($12,461)
  14. 4 Grant or award Chief Medical Officer acquired 46,250 shares (grant or award)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Derivatives Options or other derivatives
  17. 3 Insider Initial Statement of Ownership
  18. 4 Grant or award SVP, Finance & Accounting acquired 42,500 shares (grant or award)
  19. 4 Grant or award Chief Legal Officer acquired 46,250 shares (grant or award)
  20. 4 Grant or award Chief Commercial Officer acquired 46,250 shares (grant or award)

Page 4 of 14 · 277 filings